ArticleEndocrine connections2025
A predictive nomogram for treatment response in osteonecrosis patients receiving denosumab with UKA: integrating bone turnover markers and functional parameters.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary spontaneous osteonecrosis of the knee (SONK) is a debilitating condition that primarily affects elderly patients with an unknown etiology. Denosumab has emerged as a novel therapeutic agent for osteoporosis treatment. This study aimed to investigate whether denosumab improves knee function and osteoporosis in SONK patients undergoing unicompartmental knee arthroplasty (UKA). Methods: Between January 1, 2018, and December 31, 2022, patients with knee osteonecrosis undergoing UKA were enrolled. Thirty-five patients (Group A) received vitamin D3 and calcium supplements only, while 36 patients (Group B) received subcutaneous denosumab (60 mg every 6 months) plus supplements. Patients were evaluated through serum biomarkers, clinical examination, radiography, and MRI. A predictive model was developed using the least absolute shrinkage and selection operator (LASSO) regression. Results: The mean follow-up was 2.11 ± 0.99 years. One patient developed tibial plateau collapse and fibular head fracture. At 24 months, Group B showed significantly better HSS scores (T = 15.07, P = 0.04), VAS scores (T = 1.11, P = 0.04), and ROM (T = 15.07, P = 0.02) compared to Group A. Group B exhibited higher PTH levels at 12, 18, and 24 months, and higher OCN levels at 18 and 24 months. At 24 months, Group B had lower CTX but higher T-scores and BMD. Radiographic analysis revealed component malposition in some cases, with a mean postoperative femoral angle of 176.1° ± 2.3°. The prediction nomogram incorporating CTX, BMD, and ROM showed excellent discrimination (C-index = 0.925, 95% CI: 0.881-0.969), confirmed by internal validation (C-index = 0.97). Conclusion: Clinically, the 7-point improvement in HSS scores observed in Group B corresponds to a transition from 'poor' to 'good' knee function, while the 0.8-unit increase in femoral neck T-score translates into a 30% reduction in major-fracture risk over 10 years (FRAX-adjusted), indicating meaningful gains in patient mobility, pain relief, and long-term skeletal protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.